Mantle Cell Lymphoma News

This RSS feed URL is deprecated


This RSS feed URL is deprecated, please update. New URLs can be found in the footers at https://news.google.com/news

Experts Exploring BTK Inhibitor Combinations in Mantle Cell Lymphoma - Targeted Oncology



Targeted Oncology
 
Experts Exploring BTK Inhibitor Combinations in Mantle Cell Lymphoma 
Targeted Oncology
As there are now 2 BTK inhibitors approved for the treatment of patients with mantle cell lymphoma, acalabrutinib (Calquence) and ibrutinib (Imbruvica), questions remain on which agent should be given first. There are currently no head-to-head ...

 


Acalabrutinib in relapsed or refractory mantle cell lymphoma - Pharmacy Today, American Pharmacists Association, pharmacist.com



Acalabrutinib in relapsed or refractory mantle cell lymphoma 
Pharmacy Today, American Pharmacists Association, pharmacist.com
Bruton tyrosine kinase (BTK) is implicated in mantle cell lymphoma, making BTK inhibitors a likely treatment mechanism. Building on earlier work demonstrating the high potency and selectivity of the BTK inhibitor acalabrutinib, researchers launched a ...

 


New Targeted Therapy Approved for Adults With Mantle Cell Lymphoma - Everyday Health, Inc. (blog)



Everyday Health, Inc. (blog)
 
New Targeted Therapy Approved for Adults With Mantle Cell Lymphoma 
Everyday Health, Inc. (blog)
The Food and Drug Adminsitration (FDA) has granted accelerated approval for Calquence (acalabrutinib) for adults who have been previously treated for mantle cell lymphoma. This type of B-cell non-Hodgkin lymphoma tends to grow more quickly than other ...

and more » 


Highlights from ASH 2017: Mantle Cell Lymphoma - OncLive - OncLive



OncLive
 
Highlights from ASH 2017: Mantle Cell Lymphoma - OncLive 
OncLive
Alexey V. Danilov, MD, PhD; Andre Goy, MD; John P. Leonard, MD; John M. Pagel, MD, PhD, DSc; and Stephen J. Schuster, MD, share take-home messages from the 59th ASH Annual Meeting, specific to the management of mantle cell lymphoma.

and more » 


Investigational Treatment in Mantle Cell Lymphoma - OncLive - OncLive



OncLive
 
Investigational Treatment in Mantle Cell Lymphoma - OncLive 
OncLive
Alexey V. Danilov, MD, PhD; Andre Goy, MD; John P. Leonard, MD; John M. Pagel, MD, PhD, DSc; and Stephen J. Schuster, MD, consider classes of therapy that appear promising for the future management of mantle cell lymphoma.

and more » 


Acalabrutinib in Relapsed Mantle Cell Lymphoma - OncLive



OncLive
 
Acalabrutinib in Relapsed Mantle Cell Lymphoma 
OncLive
John P. Leonard, MD: Now we have very recent data with the approval of acalabrutinib, a new Bruton's tyrosine kinase inhibitor for mantle cell lymphoma. We had some updated data presented here at this meeting. I think that there are some similarities ...

 


Dr. Hill Discusses BTK Inhibitors in Mantle Cell Lymphoma - OncLive



OncLive
 
Dr. Hill Discusses BTK Inhibitors in Mantle Cell Lymphoma 
OncLive
Brian T. Hill, MD, PhD, assistant professor, Hematology and Oncology, Cleveland Clinic, discusses BTK inhibitors in mantle cell lymphoma (MCL). Acalabrutinib (Calquence) joined ibrutinib (Imbruvica) in late 2017 as the second FDA-approved BTK inhibitor ...

 


Allogeneic Transplantation in Mantle Cell Lymphoma - OncLive - OncLive



OncLive
 
Allogeneic Transplantation in Mantle Cell Lymphoma - OncLive 
OncLive
John P. Leonard, MD; Stephen J. Schuster, MD; and Andre Goy, MD, discuss considerations for allogeneic stem cell transplantation in relapsed mantle cell lymphoma.

and more » 


Ibrutinib Continues to Demonstrate Effectiveness in MCL - OncLive



OncLive
 
Ibrutinib Continues to Demonstrate Effectiveness in MCL 
OncLive
Ibrutinib (Imbruvica) has been approved by the FDA for patients with relapsed/refractory mantle cell lymphoma (MCL) since 2013, and long-term follow-up data for the BTK inhibitor continue to demonstrate its clinical activity. Results of a pooled ...

 


Triple Combo Therapy Improves Outcomes for Certain Mantle Cell Lymphoma Patients - Lymphoma News Today



Lymphoma News Today
 
Triple Combo Therapy Improves Outcomes for Certain Mantle Cell Lymphoma Patients 
Lymphoma News Today
In prior Phase 2 and Phase 3 trials for mantle cell lymphoma patients, Imbruvica has shown promising activity, with 65 to 75 percent of patients achieving a confirmed response. The therapy also showed a good tolerability profile. Similarly, a ...